Benjamin Damazo, MD
Otolaryngology · Allen, TXNPI 1598298010
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (59.1%), food and beverage and education — rather than concentrated in one kind of arrangement. Acclarent, Inc accounts for 67.2% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2024 at $1,271 and has fallen 74.9% since, to $320 in 2025. That places this record below the midpoint for otolaryngology clinicians in TX, where the typical reported total is $1,798.
Across 26 payments — averaging $61.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acclarent, Inc$1K
- Sanofi$151
- Neurent Medical Limited$119
- Sanofi-aventis U.S. LLC$53
- Aerin Medical Inc.$45
- Regeneron Healthcare Solutions, Inc.$38
- plus $121 from 6 others
What the payments were for
- Travel & lodging$95059%
- Food & beverage$60237%
- Education$533%
- Gifts$40%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Acclarent, Inc | 8 | $1,081 |
| Sanofi | 6 | $151 |
| Neurent Medical Limited | 1 | $119 |
| Sanofi-aventis U.S. LLC | 1 | $53 |
| Aerin Medical Inc. | 2 | $45 |
| Regeneron Healthcare Solutions, Inc. | 2 | $38 |
| Stryker | 1 | $31 |
| Integra Lifesciences Corporation | 1 | $23 |
| Medtronic | 1 | $21 |
| GSK | 1 | $17 |
| Phadia US Inc. | 1 | $15 |
| KARL Storz Endoscopy-america | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,609 in reported general payments places this provider in the 45th percentile of 729 otolaryngology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 15 | $149 |
| Gabapentin | 20 | $66 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in Allen
- Marc DeanFort Worth$486K
- Amber LuongHouston$426K
- Arjuna KuperanHouston$348K
- Ronald KuppersmithCollege Station$325K
- Ron KarniHouston$317K
- Philip ChenSan Antonio$305K
- Jordan RihaniSouthlake$280K
- Keith MathenyFrisco$269K
- Martin CitardiHouston$245K
- James AtkinsSan Antonio$205K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.